Journal of Cancer Research and Therapeutics

REVIEW ARTICLE
Year
: 2022  |  Volume : 18  |  Issue : 1  |  Page : 19--26

The golden spice curcumin in cancer: A perspective on finalized clinical trials during the last 10 years


Ayse Kubra Karaboga Arslan1, Ebru Uzunhisarcıklı1, Mükerrem Betül Yerer1, Anupam Bishayee2 
1 Department of Pharmacology, Faculty of Pharmacy, Erciyes University, Kayseri, Turkey
2 Lake Erie College of Osteopathic Medicine, Bradenton, FL, USA

Correspondence Address:
Anupam Bishayee
Lake Erie College of Osteopathic Medicine, 5000 Lakewood Ranch Boulevard, Bradenton, FL 34211
USA

Curcumin, the key bioactive phytochemical present in turmeric (Curcuma longa L.), is the most studied natural compound in cancer. Preclinical studies (in vitro and in vitro) and clinical trials have demonstrated curcumin's effectiveness as an anti-inflammatory agent. The existing evidence supports that curcumin inhibits the proliferation of many types of cancer cells and can play an important role in cancer therapy. This study analyses the existing evidence in the literature on finalized clinical trials (2010–2020) related to the effect of curcumin and turmeric-derived products that focused on different types of cancers, such as chronic myeloid leukemia, multiple myeloma, prostate, colorectal and pancreatic cancer as well as cancer therapy-related complications, including oral mucositis and radiation dermatitis. Original English language articles and clinical trials published between 2010 and 2020 were searched using mainstream scholarly databases, such as PubMed, ScienceDirect, Google Scholar, and ClinicalTrials.gov. The keywords, such as “curcumin,” “turmeric,” “cancer,” “anti-inflammatory,” and “clinical trials,” were used in various combinations. A total of 21 clinical trials were selected, reviewed, and included in this study. Sixteen out of 21 clinical trials were associated with the effectiveness of curcumin or turmeric on various types of cancer, and the other five clinical trials were related to the evaluation of the efficacy of curcumin or turmeric in relieving the side effects of cancer chemotherapy and radiotherapy. The emerging data from the clinical trials confirm that curcumin has the potential for cancer prevention and intervention. However, it is not yet clear whether long-term curcumin supplementation has similar benefits.


How to cite this article:
Karaboga Arslan AK, Uzunhisarcıklı E, Yerer MB, Bishayee A. The golden spice curcumin in cancer: A perspective on finalized clinical trials during the last 10 years.J Can Res Ther 2022;18:19-26


How to cite this URL:
Karaboga Arslan AK, Uzunhisarcıklı E, Yerer MB, Bishayee A. The golden spice curcumin in cancer: A perspective on finalized clinical trials during the last 10 years. J Can Res Ther [serial online] 2022 [cited 2022 May 23 ];18:19-26
Available from: https://www.cancerjournal.net/article.asp?issn=0973-1482;year=2022;volume=18;issue=1;spage=19;epage=26;aulast=Karaboga;type=0